Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Quality Ontario. Prolaris cell cycle progression test for localized prostate cancer: a health technology assessment. Toronto: Health Quality Ontario (HQO). Ontario health technology assessment series; 17(6). 2017 Authors' conclusions We found no evidence to demonstrate the impact of the Prolaris CCP test on patient-important clinical outcomes. The limited evidence available shows that the test appears to provide information that, when considered in addition to clinical risk stratification, may change the treatment plan or actual treatment for some low- and intermediate-risk prostate cancer patients. As a result, there is insufficient data to inform the cost-effectiveness of the CCP test. Publicly funding the CCP test would result in a large incremental cost to the provincial budget. Indexing Status Subject indexing assigned by CRD MeSH Cell Division; Humans; Male; Prostatic Neoplasms; Technology Assessment, Biomedical Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Evidence Development and Standards, Health Quality Ontario, 130 Bloor Street West, 10th floor, Toronto, Ontario Canada M5S 1N5 Email: EDSinfo@hqontario.ca AccessionNumber 32017000340 Date abstract record published 04/09/2017 |